☆ 4.6 Article

Development and validation of a robust and sensitive HPLC-MS/MS method for the quantitation of MRTX849 in plasma and its application in pharmacokinetics

ANALYST (2022)

Related references

Note: Only part of the references are listed.

Article Biochemical Research Methods

Validated HPLC-MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice

Naveena Madhyastha et al.

Summary: AMG 510, the first-in-class KRAS(G12C) inhibitor, is currently in phase 2 clinical trials for treating non-small cell lung cancer patients. A sensitive, selective, and high-throughput HPLC-MS/MS method was developed and validated for the quantitation of AMG 510 in mouse plasma, and successfully applied in a pharmacokinetic study in mice.

BIOMEDICAL CHROMATOGRAPHY (2021)

Add to Collection

Meeting Abstract Oncology

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Joshua K. Sabari et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Oncology

Targeting KRAS in Cancer: Promising Therapeutic Strategies

Lisa Maria Mustachio et al.

Summary: KRAS, mutated in 25% of human cancers, is crucial for tumorigenesis. Despite difficulties in directly targeting it, success has been found in targeting other proteins in the RAS pathway. Recent findings suggest progress towards developing a direct KRAS inhibitor, highlighting the need for continued research for an optimal treatment for certain tumor types.

CANCERS (2021)

Add to Collection

Article Oncology

P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

A. Spira et al.

Journal of Thoracic Oncology (2021)

Add to Collection

Review Oncology

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches

M. Reck et al.

Summary: KRAS is the most frequently mutated oncogene in human cancer, accounting for 85% of RAS mutations, yet there are no approved targeted therapies specifically for it. Promising direct KRAS(G12C) inhibitors such as sotorasib and adagrasib have shown clinical activity in previously treated patients, signaling a new era in the treatment of KRAS-mutated NSCLC.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

J. Tabernero et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Biochemical Research Methods

Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

Irene A. Retmana et al.

Summary: Sotorasib, a KRAS inhibitor, was accurately quantified in mouse plasma and various tissues using a liquid chromatography-tandem mass spectrometric method. The method showed a linear calibration range, high accuracy, and precision, and was successfully applied in investigating the pharmacokinetics and tissue accumulation of Sotorasib in female wild-type mice.

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2021)

Add to Collection

Meeting Abstract Oncology

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.

Tony S. K. Mok et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Chemistry, Medicinal

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Jay B. Fell et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients

Dongsung Kim et al.

CELL (2020)

Add to Collection

Article Oncology

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

M.L. Johnson et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Review Biochemistry & Molecular Biology

KRasG12C inhibitors in clinical trials: a short historical perspective

Lisa Goebel et al.

RSC MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Biochemical Research Methods

Optimized UPLC-MS/MS method for the quantitation of olanzapine in human plasma: application to a bioequivalence study

Ping Du et al.

BIOANALYSIS (2019)

Add to Collection

Article Chemistry, Analytical

A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study

Ping Du et al.

ANALYST (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Drugging the undruggable RAS: Mission Possible?

Adrienne D. Cox et al.

NATURE REVIEWS DRUG DISCOVERY (2014)

Add to Collection

Review Oncology

A Comprehensive Survey of Ras Mutations in Cancer

Ian A. Prior et al.

CANCER RESEARCH (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.